Sulphasalazine inhibits human antigen-specific immune responses in vivo

Annals of the Rheumatic Diseases

Volumn 66, Issue 4, 2007, Pages 481-485

  Trollmo, Christina ^a,b   Gudmundsson, Sveinn ^c   Feltelius, Nils ^b   Rogberg, Siv ^b   Smedegård, Göran ^d   Klareskog, Lars ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VACCINE; PLACEBO; SALAZOSULFAPYRIDINE; TETANUS TOXOID;

ADULT; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; MIDDLE AGED; SULFASALAZINE; TETANUS TOXOID;

EID: 34147219504     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.059881     Document Type: Article

References (31)

1. Cannella AC, O'Dell JR. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Curr Opin Rheumatol 2003;15:185.
2. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913.
3. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164.
4. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulpnasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082.
5. Aletaha DT, Stamm T, Kapral G, Eberl J, Grisar K, Machold P, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944.
6. Farr M, Bacon PA, Coppock J, Scott DL. Long term experience of salazopyrin EN in rheumatoid arthritis (RA). Scand J Rheumatol Suppl 1987;64:37.
7. Feltelius N, Hallgren R. Sulpnasalazine in ankylosing spondylitis. Ann Rheum Dis 1986;45:396.
8. Symmons DP, Salmon M, Farr M, Bacon PA. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol 1988;15:575.
9. Bird HA, Dixon JS, Pickup ME, Rhind VM, Lowe JR, Lee MR, et al. A biochemical assessment of sulpnasalazine in rheumatoid arthritis. J Rheumatol 1982;9:36.
10. Kang BY, Chung SW, Im SY, Choe YK, Kim TS. Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology 1999;98:98.
11. Klareskog L, Holmdahl R, Goldschmidt T, Bjork J. Immunoregulation in arthritis. A review on synovial immune reactions in RA and in some experimental animal models for arthritis. Scand J Rheumatol Suppl 1987;64:7.
12. Fujiwara M, Mitsui K, Ishida J, Yamamoto I. The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells. Immunopharmacology 1990;19:15.
13. Imai F, Suzuki T, Ishibashi T, Dohi Y. Effect of sulfasalazine on B cells. Clin Exp Rheumatol 1991;9:259.
14. Comer SS, H. E. Jasin. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol 1988;15:580.
15. MacDermott RP, Nash GS, Bertovich MJ, Mohrman RF, Kodnerv DL. Delacroix 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology 1986;91:379.
16. Bissonnette EY, Enciso JA, Befus AD. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol 1996;156:218.
17. Hasko G, Szabo C, Nemeth ZH, Deitch EA. Sulpnasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 2001;103:473.
18. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163.
19. Pullar T, Hunter JA, Capell HA. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol 1985;24:269.
20. Sheldon PJ, Webb C, Grindulis KA. Sulphasalazine in rheumatoid arthritis: pointers to a gut-mediated immune effect. Br J Rheumatol 1987;26:318.
21. Feltelius N, Gudmundsson S, Wennersten L, Sjoberg O, Hallgren R, Klareskog L. Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides. Ann Rheum Dis 1991;50:369.
22. Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun 1991;59:996.
23. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7:265.
24. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Mucosal immunity: implications for vaccine development. Immunobiology 1992;184:157.
25. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65:109.
26. Tarkowski A, Czerkinsky C, Nilsson LA. Simultaneous induction of rheumatoid factor- and antigen-specific antibody-secreting cells during the secondary immune response in man. Clin Exp Immunol 1985;61:379.
27. Czerkinsky C, Prince SJ, Michalek SM, Jackson S, Russell MW, Moldoveanu Z, et al. IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A 1987;84:2449.
28. Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987;40:153.
29. Picker U, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992;10:561.
30. McConkey B, Amos RS, Durham S, Forster PJ, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J 1980;280:442.
31. MacDermott RP, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 1989;96:442.